LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 51

Search options

  1. Article ; Online: Mirror-Image Phage Display for the Selection of D-Amino Acid Peptide Ligands as Potential Therapeutics.

    Malhis, Marwa / Funke, Susanne Aileen

    Current protocols

    2024  Volume 4, Issue 2, Page(s) e957

    Abstract: In neurodegenerative diseases like Alzheimer's disease (AD), endogenous proteins or peptides aggregate with themselves. These proteins may lose their function or aggregates and/or oligomers can obtain toxicity, causing injury or death to cells. ... ...

    Abstract In neurodegenerative diseases like Alzheimer's disease (AD), endogenous proteins or peptides aggregate with themselves. These proteins may lose their function or aggregates and/or oligomers can obtain toxicity, causing injury or death to cells. Aggregation of two major proteins characterizes AD. Amyloid-β peptide (Aβ) is deposited in amyloid plaques within the extracellular space of the brain and Tau in so-called neurofibrillary tangles in neurons. Finding peptide ligands to halt protein aggregation is a promising therapeutical approach. Using mirror-image phage display with a commercially available, randomized 12-mer peptide library, we have selected D-amino acid peptides, which bind to the Tau protein and modulate its aggregation in vitro. Peptides can bind specifically and selectively to a target molecule, but natural L-amino acid peptides may have crucial disadvantages for in vivo applications, as they are sensitive to protease degradation and may elicit immune responses. One strategy to circumvent these disadvantages is the use of non-naturally occurring D-amino acid peptides as they exhibit increased protease resistance and generally do not activate the immune system. To perform mirror-image phage display, the target protein needs to be synthesized as D-amino acid version. If the target protein sequence is too long to be synthesized properly, smaller peptides derived from the full length protein can be used for the selection process. This also offers the possibility to influence the binding region of the selected D-peptides in the full-length target protein. Here we provide the protocols for mirror-image phage display selection on the PHF6* peptide of Tau, based on the commercially available Ph.D.™-12 Phage Display Peptide Library Kit, leading to D-peptides that also bind the full length Tau protein (Tau441), next to PHF6*. In addition, we provide protocols and data for the first characterization of those D-peptides that inhibit Tau aggregation in vitro. © 2024 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Mirror image phage display selection against D-PHF6* fibrils Support Protocol 1: Single phage ELISA Basic Protocol 2: Sequencing and D-peptide generation Basic Protocol 3: Thioflavin-T (ThT) test to control inhibition of Tau aggregation Support Protocol 2: Purification of full-length Tau protein Basic Protocol 4: ELISA to demonstrate the binding of the generated D-peptides to PHF6* and full-length Tau fibrils.
    MeSH term(s) Humans ; tau Proteins/genetics ; tau Proteins/chemistry ; tau Proteins/metabolism ; Amino Acids ; Peptide Library ; Amyloid beta-Peptides/chemistry ; Amyloid beta-Peptides/genetics ; Amyloid beta-Peptides/metabolism ; Alzheimer Disease/drug therapy ; Alzheimer Disease/metabolism ; Peptide Hydrolases/metabolism ; Bacteriophages/metabolism
    Chemical Substances tau Proteins ; Amino Acids ; Peptide Library ; Amyloid beta-Peptides ; Peptide Hydrolases (EC 3.4.-)
    Language English
    Publishing date 2024-02-19
    Publishing country United States
    Document type Journal Article
    ISSN 2691-1299
    ISSN (online) 2691-1299
    DOI 10.1002/cpz1.957
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.

    Aillaud, Isabelle / Funke, Susanne Aileen

    Cellular and molecular neurobiology

    2022  Volume 43, Issue 3, Page(s) 951–961

    Abstract: Alzheimer disease (AD) is the most common progressive neurodegenerative disorder. AD causes enormous personal and economic burden to society as currently only limited palliative therapeutic options are available. The pathological hallmarks of the disease ...

    Abstract Alzheimer disease (AD) is the most common progressive neurodegenerative disorder. AD causes enormous personal and economic burden to society as currently only limited palliative therapeutic options are available. The pathological hallmarks of the disease are extracellular plaques, composed of fibrillar amyloid-β (Aβ), and neurofibrillary tangles inside neurons, composed of Tau protein. Until recently, the search for AD therapeutics was focussed more on the Aβ peptide and its pathology, but the results were unsatisfying. As an alternative, Tau might be a promising therapeutic target as its pathology is closely correlated to clinical symptoms. In addition, pathological Tau aggregation occurs in a large group of diseases, called Tauopathies, and in most of them Aβ aggregation does not play a role in disease pathogenesis. The formation of Tau aggregates is triggered by two hexapeptide motifs within Tau; PHF6* and PHF6. Both fragments are interesting targets for the development of Tau aggregation inhibitors (TAI). Peptides represent a unique class of pharmaceutical compounds and are reasonable alternatives to chemical substances or antibodies. They are attributed with high biological activity, valuable specificity and low toxicity, and often are developed as drug candidates to interrupt protein-protein interactions. The preparation of peptides is simple, controllable and the peptides can be easily modified. However, their application may also have disadvantages. Currently, a few peptide compounds acting as TAI are described in the literature, most of them developed by structure-based design or phage display. Here, we review the current state of research in this promising field of AD therapy development.
    MeSH term(s) Humans ; Alzheimer Disease/metabolism ; tau Proteins/metabolism ; Tauopathies/metabolism ; Neurofibrillary Tangles/metabolism ; Amyloid beta-Peptides/metabolism
    Chemical Substances tau Proteins ; Amyloid beta-Peptides
    Language English
    Publishing date 2022-05-21
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 283404-2
    ISSN 1573-6830 ; 0272-4340
    ISSN (online) 1573-6830
    ISSN 0272-4340
    DOI 10.1007/s10571-022-01230-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Selection of Listeria monocytogenes InlA-Binding Peptides Using Phage Display—Novel Compounds for Diagnostic Applications?

    Kenzel, Julia / Brüggemann, Dagmar Adeline / Funke, Susanne Aileen

    2022  

    Keywords Text ; ddc:660
    Language English
    Publishing date 2022-11-10
    Publisher MDPI AG
    Publishing country de
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Book ; Online ; Thesis: Neue Perspektive in der Therapie der Alzheimerschen Demenz – Identifizierung und Charakterisierung von Peptiden als Tau-Aggregationsinhibitoren

    Aillaud, Isabelle [Verfasser] / Funke, Susanne Aileen [Akademischer Betreuer] / Eichler, Jutta [Gutachter]

    2022  

    Author's details Isabelle Aillaud ; Gutachter: Jutta Eichler ; Betreuer: Susanne Aileen Funke
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language German
    Publisher Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
    Publishing place Erlangen
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  5. Book ; Online ; Thesis: Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer’s disease

    Malhis, Marwa [Verfasser] / Funke, Susanne Aileen [Akademischer Betreuer]

    2021  

    Author's details Marwa Malhis ; Betreuer: Susanne Aileen Funke
    Keywords Biowissenschaften, Biologie ; Life Science, Biology
    Subject code sg570
    Language English
    Publisher Universität Bayreuth
    Publishing place Bayreuth
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  6. Article ; Online: Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease.

    Funke, Susanne Aileen

    International journal of Alzheimer's disease

    2011  Volume 2011, Page(s) 151645

    Abstract: The diagnosis of probable Alzheimer's disease (AD) can be established premortem based on clinical criteria like neuropsychological tests. Post mortem, specific neuropathological changes like amyloid plaques define AD. However, the standard criteria based ...

    Abstract The diagnosis of probable Alzheimer's disease (AD) can be established premortem based on clinical criteria like neuropsychological tests. Post mortem, specific neuropathological changes like amyloid plaques define AD. However, the standard criteria based on medical history and mental status examinations do not take into account the long preclinical features of the disease, and a biomarker for improved diagnosis of AD is urgently needed. In a large number of studies, amyloid-β (Aβ) monomer concentrations in CSF of AD patients are consistently and significantly reduced when compared to healthy controls. Therefore, monomeric Aβ in CSF was suggested to be a helpful biomarker for the diagnosis of preclinical AD. However, not the monomeric form, but Aβ oligomers have been shown to be the toxic species in AD pathology, and their quantification and characterization could facilitate AD diagnosis and therapy monitoring. Here, we review the current status of assay development to reliably and routinely detect Aβ oligomers and high-molecular-weight particles in CSF.
    Language English
    Publishing date 2011-11-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2573333-3
    ISSN 2090-0252 ; 2090-8024
    ISSN (online) 2090-0252
    ISSN 2090-8024
    DOI 10.4061/2011/151645
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid.

    Schuster, Judith / Funke, Susanne Aileen

    Journal of Alzheimer's disease : JAD

    2016  Volume 53, Issue 1, Page(s) 53–67

    Abstract: Protein misfolding and aggregation are fundamental features of the majority of neurodegenerative diseases, like Alzheimer's disease (AD), Parkinson's disease, frontotemporal dementia, and prion diseases. Proteinaceous deposits in the brain of the patient, ...

    Abstract Protein misfolding and aggregation are fundamental features of the majority of neurodegenerative diseases, like Alzheimer's disease (AD), Parkinson's disease, frontotemporal dementia, and prion diseases. Proteinaceous deposits in the brain of the patient, e.g., amyloid plaques consisting of the amyloid-β (Aβ) peptide and tangles composed of tau protein, are the hallmarks of AD. Soluble oligomers of Aβ and tau play a fundamental role in disease progression, and specific detection and quantification of the respective oligomeric proteins in cerebrospinal fluid may provide presymptomatically detectable biomarkers, paving the way for early diagnosis or even prognosis. Several studies on the development of techniques for the specific detection of Aβ oligomers were published, but some of the existing tools do not yet seem to be satisfactory, and the study results are contradicting. The detection of oligomers is challenging due to their polymorphous and unstable nature, their low concentration, and the presence of competing proteins and Aβ monomers in body fluids. Here, we present an overview of the current state of the development of methods for Aβ oligomer specific detection and quantitation. The methods are divided in the three subgroups: (i) enzyme linked immunosorbent assays (ELISA), (ii) methods for single oligomer detection, and (iii) others, which are mainly biosensor based methods.
    Language English
    Publishing date 2016-05-07
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-151029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF

    Susanne Aileen Funke

    International Journal of Alzheimer's Disease, Vol

    Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease

    2011  Volume 2011

    Keywords Geriatrics ; RC952-954.6 ; Special situations and conditions ; RC952-1245 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Internal medicine ; DOAJ:Medicine (General) ; DOAJ:Health Sciences ; Neurosciences. Biological psychiatry. Neuropsychiatry ; RC321-571 ; DOAJ:Neurology
    Language English
    Publishing date 2011-01-01T00:00:00Z
    Publisher Hindawi Publishing Corporation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro.

    Aillaud, Isabelle / Kaniyappan, Senthilvelrajan / Chandupatla, Ram Reddy / Ramirez, Lisa Marie / Alkhashrom, Sewar / Eichler, Jutta / Horn, Anselm H C / Zweckstetter, Markus / Mandelkow, Eckhard / Sticht, Heinrich / Funke, Susanne Aileen

    Alzheimer's research & therapy

    2022  Volume 14, Issue 1, Page(s) 15

    Abstract: Background: Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults. One of the pathological hallmarks of AD is abnormally aggregated Tau protein that forms fibrillar ... ...

    Abstract Background: Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults. One of the pathological hallmarks of AD is abnormally aggregated Tau protein that forms fibrillar deposits in the brain. In AD, Tau pathology correlates strongly with clinical symptoms, cognitive dysfunction, and neuronal death.
    Methods: We aimed to develop novel therapeutic D-amino acid peptides as Tau fibrillization inhibitors. It has been previously demonstrated that D-amino acid peptides are protease stable and less immunogenic than L-peptides, and these characteristics may render them suitable for in vivo applications. Using a phage display procedure against wild type full-length Tau (Tau
    Results: While ISAD1rev inhibited Tau aggregation only moderately, ISAD1 bound to Tau in the aggregation-prone PHF6 region and inhibited fibrillization of Tau
    Conclusions: ISAD1 and related peptides may be suitable for therapy development of AD by promoting off-pathway assembly of Tau, thus preventing its toxicity.
    MeSH term(s) Aged ; Alzheimer Disease/drug therapy ; Alzheimer Disease/pathology ; Amino Acids/therapeutic use ; Cells, Cultured ; Humans ; Peptides/therapeutic use ; Protein Conformation, beta-Strand ; tau Proteins/metabolism ; tau Proteins/toxicity
    Chemical Substances Amino Acids ; Peptides ; tau Proteins
    Language English
    Publishing date 2022-01-21
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2506521-X
    ISSN 1758-9193 ; 1758-9193
    ISSN (online) 1758-9193
    ISSN 1758-9193
    DOI 10.1186/s13195-022-00959-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Peptides for therapy and diagnosis of Alzheimer's disease.

    Funke, Susanne Aileen / Willbold, Dieter

    Current pharmaceutical design

    2012  Volume 18, Issue 6, Page(s) 755–767

    Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with devastating effects. The greatest risk factor to develop AD is age. Today, only symptomatic therapies are available. Additionally, AD can be diagnosed with certainty only post ... ...

    Abstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder with devastating effects. The greatest risk factor to develop AD is age. Today, only symptomatic therapies are available. Additionally, AD can be diagnosed with certainty only post mortem, whereas the diagnosis "probable AD" can be established earliest when severe clinical symptoms appear. Specific neuropathological changes like neurofibrillary tangles and amyloid plaques define AD. Amyloid plaques are mainly composed of the amyloid-βpeptide (Aβ). Several lines of evidence suggest that the progressive concentration and subsequent aggregation and accumulation of Aβ play a fundamental role in the disease progress. Therefore, substances which bind to Aβ and influence aggregation thereof are of great interest. An enormous number of organic substances for therapeutic purposes are described. This review focuses on peptides developed for diagnosis and therapy of AD and discusses the pre- and disadvantages of peptide drugs.
    MeSH term(s) Alzheimer Disease/diagnosis ; Alzheimer Disease/drug therapy ; Amino Acid Sequence ; Amyloid beta-Protein Precursor ; Drug Discovery ; Humans ; Peptide Library ; Peptides/therapeutic use
    Chemical Substances Amyloid beta-Protein Precursor ; Peptide Library ; Peptides
    Language English
    Publishing date 2012-01-28
    Publishing country United Arab Emirates
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1304236-1
    ISSN 1873-4286 ; 1381-6128
    ISSN (online) 1873-4286
    ISSN 1381-6128
    DOI 10.2174/138161212799277752
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top